Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China

Cancer Epidemiology

Volumn 32, Issue 5-6, 2009, Pages 416-423

  Song, Dong Kui ^a   Xing, Dong Liang ^b   Zhang, Li Rong ^b   Li, Zhong Xue ^a   Liu, Jian ^a   Qiao, Bao Ping ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Bladder cancer; CYP2A13; CYP2A6; GST; NAT2; Polymorphism

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 2A6; GLUTATHIONE TRANSFERASE;

ADULT; AGED; ALLELE; ARTICLE; BLADDER CANCER; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER RISK; CHINA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; CHINA; DISEASE SUSCEPTIBILITY; FEMALE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; POLYMORPHISM, GENETIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 67349262481     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cdp.2009.02.003     Document Type: Article

References (50)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics 2002. CA Cancer J Clin 55 (2005) 74-108
2. Yang L., Parkin D.M., Li L.D., Chen Y.D., and Bray F. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer 90 (2004) 2157-2166
3. Cohen S.M., Shirai T., and Steineck G. Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol Suppl 205 (2000) 105-115
4. Pashos C.L., Botteman M.F., Laskin B.L., and Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract 10 (2002) 311-322
5. Zeegers M.P., Kellen E., Buntinx F., and van den Brandt P.A. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol 21 (2004) 392-401
6. Probst-Hensch N.M., Bell D.A., Watson M.A., Skipper P.L., Tannenbaum S.R., Chan K.K., et al. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomarkers Prev 9 (2000) 619-623
7. Badawi A.F., Hirvonen A., Bell D.A., Lang N.P., and Kadlubar F.F. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 55 (1995) 5230-5237
8. Kadlubar F.F., and Badawi A.F. Genetic susceptibility and carcinogen-DNA adduct formation in human urinary bladder carcinogenesis. Toxicol Lett 82-83 (1995) 627-632
9. Ma Q.W., Lin G.F., Chen J.G., Xiang C.Q., Guo W.C., Golka K., et al. Polymorphism of N-acetyltransferase 2 (NAT2) gene polymorphism in shanghai population: occupational and non-occupational bladder cancer patient groups. Biomed Environ Sci 17 (2004) 291-298
10. Garcia-Closas M., Malats N., Silverman D., Dosemeci M., Kogevinas M., Hein D.W., et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366 (2005) 649-659
11. Marcus P.M., Vineis P., and Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics 10 (2000) 115-122
12. Okkels H., Sigsgaard T., Wolf H., and Autrup H. Arylamine N-acetyltransferase1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev 6 (1997) 225-231
13. Taylor J.A., Umbach D.M., Stephens E., Castranio T., Paulson D., Robertson C., et al. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res 58 (1998) 3603-3610
14. Hung R.J., Boffetta P., Brennan P., Malaveille C., Hautefeuille A., Donato F., et al. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer 110 (2004) 598-604
15. Gu J., Liang D., Wang Y., Lu C., and Wu X. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutat Res 581 (2005) 97-104
16. Kim W.J., Lee H.L., Lee S.C., Kim Y.T., and Kim H. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis. J Urol 164 (2000) 209-213
17. Bell D.A., Taylor J.A., Paulson D.F., Robertson C.N., Mohler J.L., and Lucier G.W. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 85 (1993) 1159-1164
18. Pemble S., Schroeder K.R., Spencer S.R., Meyer D.J., Hallier E., Bolt H.M., et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300 (1994) 271-276
19. Rebbeck T.R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 6 (1997) 733-743
20. Johns L.E., and Houlston R.S. Glutathione S-transferase mu1 (GSTM1) status and bladder cancer risk: a meta-analysis. Mutagenesis 15 (2000) 399-404
21. Engel L.S., Taioli E., Pfeiffer R., Garcia-Closas M., Marcus P.M., Lan Q., et al. Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol 156 (2002) 95-109
22. Brockmoller J., Cascorbi I., and Kerb R. Roots I Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 56 (1996) 3915-3925
23. Kempkes M., Golka K., Reich S., Reckwitz T., and Bolt H.M. Glutathione Stransferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Arch Toxicol 71 (1996) 123-126
24. Salagovic J., Kalina I., Habalova V., Hrivnák M., Valanský L., and Biros E. The role of human glutathione S-transferases M1 and T1 in individual susceptibility to bladder cancer. Physiol Res 48 (1999) 465-471
25. Giannakopoulos X., Charalabopoulos K., Baltogiannis D., Chatzikiriakidou A., Alamanos Y., Georgiou I., et al. The role of N-acetyltransferase-2 and glutathione S-transferase on the risk and aggressiveness of bladder cancer. Anticancer Res 22 (2002) 3801-3804
26. Kim W.J., Kim H., Kim C.H., Lee M.S., Oh B.R., Lee H.M., et al. GSTT1-null genotype is a protective factor against bladder cancer. Urology 60 (2002) 913-918
27. Lee S.J., Cho S.H., Park S.K., Kim S.W., Park M.S., Choi H.Y., et al. Combined effect of glutathione S-transferase M1 and T1 genotypes on bladder cancer risk. Cancer Lett 177 (2002) 173-179
28. Ma Q.W., Lin G.F., Chen J.G., and Shen J.H. Polymorphism of glutathione S-transferase T1 M1 and P1 genes in a Shanghai population: patients with occupational or non-occupational bladder cancer. Biomed Environ Sci 15 (2002) 253-260
29. Karagas M.R., Park S., Warren A., Hamilton J., Nelson H.H., Mott L.A., et al. Gender, smoking, glutathione-S-transferase variants and bladder cancer incidence: a population-based study. Cancer Lett 219 (2005) 63-69
30. Su T., Bao Z., Zhang Q.Y., Smith T.J., Hong J.Y., and Ding X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 60 (2000) 5074-5079
31. Bao Z., He X.Y., Ding X., Prabhu S., and Hong J.Y. Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab Dispos 33 (2005) 258-261
32. Miyamoto M., Umetsu Y., Dosaka-Akita H., Sawamura Y., Yokota J., Kunitoh H., et al. CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem Biophys Res Commun 261 (1999) 658-660
33. Ishizaki T., and Kamataki T. Twenty one novel single polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians. Drug Metab Pharmacokinet 17 (2002) 453-458
34. Zhang X., Su T., Zhang Q.Y., Gu J., Caggana M., Li H., et al. Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J Pharmacol Exp Ther 302 (2002) 416-423
35. Tan W., Chen G.F., Xing D.Y., Song C.Y., Kadlubar F.F., and Lin D.X. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int J Cancer 95 (2001) 96-101
36. Wang H., Tan W., Hao B., Miao X., Zhou G., He F., et al. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 63 (2003) 8057-8061
37. Fujieda M., Yamazaki H., Saito T., Kiyotani K., Gyamfi M.A., Sakurai M., et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 25 (2004) 2451-2458
38. Schlicht K.E., Michno N., Smith B.D., Scott E.E., and Murphy S.E. Functional characterization of CYP2A13 polymorphisms. Xenobiotica 37 (2007) 1439-1449
39. Sobin L.H., and Wittekind C. International Union Against Cancer (UICC). TNM classification of malignant tumours. 5th ed. (1997), Wiley-Liss, New York p. 187-90
40. Schroeder J.C., Conway K., Kusum-Mistry Y.L., Mistry K., Bell D.A., and Taylor J.A. P53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors. Cancer Res 63 (2003) 7530-7538
41. Loktionov A., Moore W., Spencer S.P., Vorster H., Nell T., O'Neill I.K., et al. Differences in N-acetylation genotypes between Caucasians and Black South Africans: implications for cancer prevention. Cancer Detect Prev 26 (2002) 15-22
42. Bell D.A., Taylor J.A., Butler M.A., Stephens E.A., Wiest J., Brubaker L.H., et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African Americans. Carcinogenesis 14 (1993) 1689-1692
43. García-Closas M., Kelsey K.T., Hankinson S.E., Spiegelman D., Springer K., Willett W.C., et al. Glutathione S-transferase mu and theta polymorphisms and breast cancer susceptibility. J Natl Cancer Inst 91 (1999) 1960-1964
44. Miller M.C., Mohrenweiser H.W., and Bell D.A. Genetic variability in susceptibility and response to toxicants. Toxicol Lett 120 (2001) 269-280
45. Vineis P., and Pirastu R. Aromatic amines and cancer. Cancer Causes Control 8 (1997) 346-355
46. Georgiou I., Filiadis I.F., Alamanos Y., Bouba I., Giannakopoulos X., and Lolis D. Glutathione S-transferase null genotypes in transitional cell bladder cancer: a case-control study. Eur Urol 37 (2000) 660-664
47. Srivastava D.S., Mishra D.K., Mandhani A., Mittal B., Kumar A., and Mittal R.D. Association of genetic polymorphism of glutathione S-transferase M1, T1 P1 and susceptibility to bladder cancer. Eur Urol 48 (2005) 339-344
48. Kamataki T., Nunoya K., Sakai Y., Kushida H., and Fujita K. Genetic polymorphism of CYP2A6 in relation to cancer. Mutat Res 428 (1999) 125-130
49. Ariyoshi N., Miyamoto M., Umetsu Y., Kunitoh H., Dosaka-Akita H., Sawamura Y., et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol Biomarkers Prev 11 (2002) 890-894
50. Tsukino H., Kuroda Y., Qiu D., Nakao H., Imai H., and Katoh T. Effects of cytochrome P-450 (CYP) 2A6 gene deletion and CYP2E1 genotypes on gastric adenocarcinoma. Int J Cancer 100 (2002) 425-428